OSLO, Norway, April 29, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces four abstract presentations at the AUA 2025, highlighting the benefits of Blue Light ...

Deion Sanders opened up about his bladder cancer diagnosis, raising awareness on symptoms, risk factors, and the importance ...

As July concludes, new treatments offer advances across kidney and bladder cancer, with breakthroughs in personalized vaccines and non-surgical therapies.

A research team led by Professor Seokho Kang of Urology (Professor Seokho Kang, Professor Shim Ji-sung, Professor Roh Tae-il, ...

More information: Changjoon Keum et al, Diagnosis of early-stage bladder cancer via unprocessed urine samples at the point of care, Nature Biomedical Engineering (2024). DOI: 10.1038/s41551-024 ...

The accuracy of fluorescence cystoscopy is also affected by previous bladder treatments. As Grimbergen demonstrated, [33] intravesical therapy within the 6-month period before fluorescence ...

NHS Lothian and Nucleix Presented Data at EAU25 Showcasing Potential of Bladder EpiCheck® to Improve Detection of Disease Recurrence in Non-Muscle Invasive Bladder Cancer (NMIBC) Patients Adding ...

Researchers determined 219 (19.9%) study participants had bladder cancer, and 176 (16%) had high-grade or invasive cancer.

Photocure ASA ( (PHCUF) ) has shared an announcement. Photocure ASA reported record revenues for its Hexvix®/Cysview® products in the second quarter of 2025, driven by strong performance in the U.S.

Bladder cancer affects approximately 83,000 Americans each year, yet remains one of the most overlooked forms of cancer despite having excellent survival rates when caught early. This disconnect ...

There is a dose-response relationship between cumulative cyclophosphamide dose and risk of bladder cancer in Wegener's granulomatosis. (Knight A et al, 2004; 63:1307-1311.) ...

In a news conference this week discussing removal of his bladder due to cancer, University of Colorado football coach Deion ...